*Sponsored by Sica Media
NMTC (NeuroOne Medical Technologies Corporation) hasn’t been getting much love recently, but it could be poised for a big reversal and breakout.
The Minnesota-based company is in the early stages of developing minimally invasive solutions for treating neurological disorders, including epilepsy, Parkinson’s disease, and essential tremor disorder.
NMTC has a huge and growing opportunity here to improve people’s lives – more than 100 million Americans are impacted by some type of neurological disorder, and that figure is expected to grow as the population ages.
The firm has achieved a couple major milestones in the past few years, including successive FDA 510(k) clearances in 2019 and 2022 for newly developed electrode technology. They also submitted an application in June for 510(k) clearance for a system to improve neurological surgeries.
The BIGGEST NEWS landed just yesterday, in fact…
NMTC has engaged several big-name firms for strategic partnerships, including Mayo Clinic and Zimmer Biomet. In all, these catalysts (plus some recent price signals) could point to a potential impending reversal in NMTC’s share price.
I think it is crucial to note the recent trading patterns.
Since the lows in November, NMTC has seen swings of more than 100%.
I think this pullback is an excellent opportunity to get NMTC on your radar and see if another breakout is around the corner?
Although that indicates there’s some institutional support for the trend-reversal idea, a stronger sentiment indicator is the volume of insider buying that’s been occurring recently.
Over the past year, insiders have bought nearly double the number of shares they’ve sold. But over the past three months, that trend has accelerated, with insiders buying shares at six times the rate they’ve sold them. That could be a big sign that insiders are looking to get more skin in the game ahead of a jump in price.
Looking at the fundamentals of a firm like NMTC doesn’t always provide the most relevant information. For medical technology companies, success is often influenced far more by impending FDA approvals or major breakthroughs – not things you’d find looking at a balance sheet.
With that said, NMTC’s fundamentals do provide some support for the view that things are taking a positive turn.
Although the company is loss-making, it did have a strong gross profit margin for the last quarter. A gross profit of $244K on $629K of revenue indicates a healthy margin in the range of 38%. With that margin, NMTC should be able to cover its operating expenses by eventually scaling sales.
Moreover, NMTC’s liabilities don’t seem to be too concerning. Its largest liabilities included accounts payable and other accrued expenses, rather than notes or bonds.
If a company is unable to satisfy debt-holders, it might get pushed into bankruptcy before it can take off – but NMTC appears to have a sizable cushion in the near term, with current assets ahead of current liabilities as of last quarter.
All trading is risky, and you should do your own research to see if NMTC is the right opportunity for you. The prospects for medical technology companies, in fact, tend to be even more uncertain than usual.
But the time could be right for a reversal in NMTC’s fortunes, representing a potentially strong trading opportunity. Here are the key factors that could push the stock price higher soon:
- Technical indicators indicate a momentum reversal. Some technical indicators are weak, representing the firm’s poor performance over the past few years. But momentum-based figures are highlighting that the stock could be oversold and ready for a change in trend.
- Strong institutional and insider sentiment. Of the two analysts covering NMTC, none are bearish. Wall Street price targets are well above the current share price, and there is one Strong Buy recommendation on the stock. Finally, insider buying activity has been solid over the past year and has picked up in the past few months.
- Growth prospects and stable fundamentals. NMTC’s recent application to the FDA for its newest developments and its growing ability to commercialize 510(k) cleared technology with solid profit margins are all good signs for the firm. As long as NMTC can make its current liquidity last, the business has a viable path to profitability and success.
As always, make sure you do your own research, and make sure you have a suitable trading plan before you ever decide to make any trades of your own.
*This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.
*PAID ADVERTISEMENT. Raging Bull has currently been paid five thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. from a period beginning on December 12 through December 12, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NeuroOne Medical Technologies Corp., increased trading volume, and possibly an increased share price of NeuroOne Medical Technologies Corp.’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NeuroOne Medical Technologies Corp., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.
FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull’s business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.
SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment.
NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/company search
TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.
WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.